大分割剂量递增放疗对比常规分割放疗治疗局限性前列腺癌:III期前瞻性随机对照试验长期更新
MD安德森剂量递增大分割前列腺放疗研究为III期随机试验,比较常规分割IMRT(75.6 Gy/1.8 Gy)与大分割剂量递增IMRT(72 Gy/2.4 Gy)在局限性前列腺癌中的疗效。中位随访13.2年显示,HIMRT组治疗失败13例 vs CIMRT组22例,差异不再有统计学意义(P=.08)。远处转移罕见且无显著差异(P=.2),晚期胃肠2+级和泌尿2+级毒性均无显著差异。
要点
- 中位随访13.2年,HIMRT组治疗失败13例 vs CIMRT组22例(P=.08),差异不再有统计学意义
- 远处转移罕见,两组无统计学显著差异(P=.2)
- 晚期胃肠2+级毒性10年发生率HIMRT 10% vs CIMRT 4%(P=.09),泌尿2+级26% vs 23%(P=.5),均无显著差异
核心结论
- 长期更新至中位随访13.2年,HIMRT组治疗失败仍少于CIMRT组(13例 vs 22例),但差异不再有统计学意义(P=.08)。
- 远处转移罕见,两组无统计学显著差异(P=.2)。
- 晚期胃肠2+级和泌尿2+级毒性两组均无统计学显著差异。
研究设计与样本
- MD安德森剂量递增大分割前列腺放疗研究为III期前瞻性随机对照试验。
- 比较常规分割IMRT(CIMRT,75.6 Gy/1.8 Gy分次)与大分割剂量递增IMRT(HIMRT,72 Gy/2.4 Gy分次)。
- 纳入局限性前列腺癌患者,以低危和中危为主。
- 本次报告长期更新13年结局,中位随访13.2年(IQR 8.8-15.9年),并事后评估远处转移。
主要发现
- 治疗失败HIMRT组13例 vs CIMRT组22例,差异不再有统计学意义(P=.08)。
- 远处转移罕见,两组无统计学显著差异(P=.2)。
- 晚期胃肠2+级毒性10年发生率HIMRT 10% vs CIMRT 4%(P=.09)。
- 晚期泌尿2+级毒性10年发生率HIMRT 26% vs CIMRT 23%(P=.5)。
关键数值与推荐
- HIMRT方案:72 Gy,2.4 Gy/分次。
- CIMRT方案:75.6 Gy,1.8 Gy/分次。
- 中位随访13.2年(IQR 8.8-15.9年)。
- 治疗失败HIMRT 13例 vs CIMRT 22例,P=.08。
- 远处转移P=.2;晚期胃肠2+级毒性10年HIMRT 10% vs CIMRT 4%(P=.09);泌尿2+级10年HIMRT 26% vs CIMRT 23%(P=.5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The MD Anderson dose-escalated, hypofractionated prostate radiation study was a phase III randomized trial comparing conventionally fractionated intensity-modulated radiation therapy (CIMRT, 75.6 Gy in 1.8-Gy fractions) with dose-escalated, hypofractionated intensity-modulated radiation (HIMRT, 72 Gy in 2.4-Gy fractions) in patients with localized prostate cancer, predominantly low-risk and intermediate-risk disease. The initial publication highlighted statistically fewer treatment failures in the HIMRT arm. We present long-term updated 13-year outcomes to determine whether cancer control benefit was maintained and to evaluate distant metastases post hoc. With a median follow-up of 13.2 years (IQR, 8.8-15.9 years), treatment failure occurred less frequently in men undergoing HIMRT (n = 13) compared with those undergoing CIMRT (n = 22), although the difference no longer meets statistical significance (P = .08). Distant metastases were rare, and no statistically significant difference was noted (P = .2). There remained no statistically significant difference in late GI 2+ (10-year 10% HIMRT v 4% CIMRT, P = .09) or genitourinary grade 2+ toxicity (10-year 26% v 23%, P = .5).
引用
- Hassanzadeh C, Kuban D, Pasyar S, et al. Hypofractionated, Dose-Escalated Radiation Versus Conventionally Fractionated Radiation for Localized Prostate Cancer: Long-Term Update of a Phase III, Prospective, Randomized Controlled Trial. J Clin Oncol. 2025. PMID: 40367400. doi:10.1200/JCO-24-02057
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。